Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer Blog

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer

Posted 29 Apr 2014 by

April 29, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib, the only other approved ALK tyrosine kinase inhibitor. Lung cancer is the leading cause of cancer-related deaths among men and women. According to the National Cancer Institute, an estimated 224,210 Americans will be diagnosed with lung cancer, and 159,260 will die from the disease this year. About 85 percent of lung cancers are NSCLC, making it the most common type of lung cancer. However, only 2-7 percent of patients with NSCLC ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer

Chemo Might Give Certain Lung Cancer Patients an Edge

Posted 8 Apr 2014 by

TUESDAY, April 8, 2014 – Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer. Now, a new analysis of existing research finds that traditional chemotherapy outperforms newer, targeted treatments in delaying the time until the cancer worsens for these patients. However, chemo doesn't extend their survival, the review found. Patients with non-small cell lung cancer make up 85 percent to 90 percent of lung cancer patients. Some of them have a mutation in a gene that makes their tumors more responsive to medications known as epidermal growth factor receptor tyrosine kinase inhibitors. But most patients with non-small cell lung cancer do not have this mutation, and doctors have been unsure whether this larger group of patients should get chemo or the targeted medication. "In our opinion, conventional chemotherapy is a better ... Read more

Related support groups: Non-Small Cell Lung Cancer

Experimental Drug Shows Promise for Drug-Resistant Lung Cancer

Posted 26 Mar 2014 by

WEDNESDAY, March 26, 2014 – A new drug may help lung cancer patients when they become resistant to the first-line medication crizotinib, researchers find. Although crizotinib (brand name Xalkori) causes regression of a specific type of lung cancer, patients become resistant to it within about a year. But the new drug, ceritinib, seems effective against this type of lung cancer – called advanced ALK-positive non-small cell lung cancer – according to the results of early trials. "Ceritinib is even effective after the first-generation drug crizotinib has stopped working," said lead researcher Dr. Alice Shaw, an associate professor of medicine at Harvard Medical School in Boston. Preliminary results from this study led the U.S. Food and Drug Administration to give ceritinib a "breakthrough therapy" designation and led the drug's manufacturer to recommend accelerated approval, she said. ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Xalkori, Crizotinib

Breath Test May Detect Signs of Lung Cancer: Study

Posted 28 Jan 2014 by

TUESDAY, Jan. 28, 2014 – A simple breath test might reveal if a person has early-stage lung cancer, according to a new study. Researchers tested the exhaled breath of people with suspicious lung lesions that were detected on CT scans. The breath was tested for levels of four cancer-specific substances, called "carbonyls." The breath samples were analyzed using a special device developed at the University of Louisville. Having elevated levels of three of the four carbonyls was predictive of lung cancer in 95 percent of patients, while having normal levels of these substances was predictive of a noncancerous growth in 80 percent of patients, the researchers found. Elevated carbonyl levels returned to normal after lung cancer patients had surgery to remove the cancer, according to the study, which was to be presented Tuesday at the Society of Thoracic Surgeons annual meeting in Orlando, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation

Gilotrif Approved for Late-Stage Lung Cancer

Posted 14 Jul 2013 by

FRIDAY, July 12 – The drug Gilotrif (afatinib) has been approved by the U.S. Food and Drug Administration to treat spreading cases of non-small cell lung cancer (NSCLC) caused by certain gene mutations, the agency said Friday. The treatment, given priority FDA review, was sanctioned for tumors that express certain epidermal growth factor receptor (EGFR) mutations, as detected by a newly approved diagnostic, the agency said in a news release. Lung cancer is the number one cause of cancer-related death in both men and women, the FDA said. The disease is likely to be diagnosed in some 228,190 people this year, and is predicted to kill about 159,480, the U.S. National Cancer Institute said. EGFR mutations are found in about 10 percent of NSCLC cases. Gilotrif is designed to block proteins that spur development of cancer cells, the FDA said. The drug was approved along with a companion ... Read more

Related support groups: Non-Small Cell Lung Cancer

New Drug May Help Fight Certain Advanced Lung Cancers

Posted 3 Jun 2013 by

MONDAY, June 3 – For patients struggling with a common and deadly form of lung cancer, adding the drug ganetespib to a standard chemotherapy drug may boost survival, new research suggests. The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it's the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients. The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology. "This is the first randomized study to demonstrate therapeutic benefit with a heat shock protein inhibitor in patients with cancer," study lead author Dr. Suresh Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, in Atlanta, said in an ASCO news release. The study focused on patients with a form of non-small cell ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

New Drug May Help Immune System Fight Cancer

Posted 16 May 2013 by

THURSDAY, May 16 – An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows. The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device. "That [the protein] allows the tumor cell to grow unchecked and cause harm to the patient," said study author Dr. Roy Herbst, chief of medical oncology at Yale University. But with the protein blocked, the immune system can see and destroy cancer cells. Of 140 patients in the pilot safety study, 29 (or 21 percent) initially saw significant tumor shrinkage after at least three months on the medication. Researchers say 26 patients have continued to respond over time, including some who have been on the drug for more than a year. One ... Read more

Related support groups: Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer

Test Approved to Detect Faulty Lung Cancer Gene

Posted 16 May 2013 by

THURSDAY, May 16 – The U.S. Food and Drug Administration has approved a test designed to detect a faulty gene that's present in about 10 percent of cases of non-small cell lung cancer (NSCLC). The cobas EGFR Mutation Test, a companion diagnostic to the approved cancer drug Tarceva (erlotinib), detects a mutation in the epidermal growth factor receptor (EGFR) gene, the FDA said in a news release. Lung cancer is the leading cause of cancer-related death for both men and women, accounting for about 228,000 annual cases in the United States. Some 85 percent of lung cancers are NSCLC, the FDA said. In approving the new diagnostic, the FDA also sanctioned expanded use for Tarceva as a first-line treatment for people with NSCLC that has spread to other parts of the body and who have the mutated gene, the agency said. The new diagnostic is produced by California-based Roche Molecular Systems. ... Read more

Related support groups: Non-Small Cell Lung Cancer, Diagnosis and Investigation

Freezing Treatment May Help Destroy Lung Tumors: Study

Posted 15 Apr 2013 by

SUNDAY, April 14 – A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds. At least in the short-run – meaning three months after the procedure – the intervention known as "cryoablation" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest. However, some patients developed new tumors in that time period, the researchers noted. The study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease. Rather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time. "'Promising' is the ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Tofu-Rich Diet May Help Women With Lung Cancer Live Longer

Posted 26 Mar 2013 by

TUESDAY, March 26 – Eating tofu and other soy foods may help women who develop lung cancer increase their odds of living longer. A study of women from Shanghai, China, published in the March 25 issue of the Journal of Clinical Oncology, links high soy consumption before a lung cancer diagnosis with longer survival. "This is the first study to suggest an association between soy food consumption and lung cancer survival," said study author Dr. Gong Yang, a research associate professor of medicine in the division of epidemiology at Vanderbilt University Medical Center, in Nashville. Eating soy products in small amounts in the years preceding a lung cancer diagnosis didn't seem to pose a benefit, though. Lung cancer is the leading cause of death among women in the world. It forms in the tissues of the lungs, usually in the cells that line the air passageways. The five-year survival rate is ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma

FDA Approves Abraxane for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Posted 12 Oct 2012 by

SUMMIT, N.J.--(BUSINESS WIRE)--Oct 12, 2012 - Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. “Non-small cell is the most common type of lung cancer, the leading cause of cancer death in the United States,” said Dr. Mark A. Socinski, MD, Director, Lung Cancer Section, Division of Hematology/Oncology, University of Pittsburgh, and lead investigator of Abraxane phase II and phase III lung cancer trials. “The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung ... Read more

Related support groups: Non-Small Cell Lung Cancer, Paclitaxel, Abraxane, Paclitaxel Protein-Bound

Abraxane Approved to Treat Advanced Lung Cancer

Posted 12 Oct 2012 by

FRIDAY, Oct. 12 – Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration – in combination with the drug carboplatin – to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday. Abraxane was first approved in 2005 to treat breast cancer. In a new clinical study of 1038 people, the most common adverse reactions to the drug were anemia, loss of hair, nausea, fatigue, loss of appetite, irregularity, rash and swelling. Abraxane is produced by Celgene Corp., based in Summit, N.J. More information To learn more about non-small cell lung cancer, visit the U.S. National Cancer Institute. Read more

Related support groups: Non-Small Cell Lung Cancer, Abraxane, Paclitaxel Protein-Bound

Targeted Radiation for Lung Cancer May Carry Risks

Posted 13 Jun 2012 by

WEDNESDAY, June 13 – A woman with early-stage lung cancer died recently after highly targeted radiation therapy zapped not just her tumor, but surrounding tissue, fatally damaging her airway. Though just a single case report of an apparently deadly complication, the authors warn that targeted radiation therapy – specifically, stereotactic body-radiation therapy – has inherent risks, even when done properly and using an even lower dose of radiation than is considered safe. Stereotactic body-radiation therapy focuses beams of radiation on a tumor in the hopes of killing it. Because it uses highly precise beams that can focus large doses of radiation with millimeter accuracy, the technique is considered an advance over older types of radiation therapy, which are generally more diffuse, explained Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. The goal ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Older Lung Cancer Patients Less Likely to Be Treated

Posted 4 May 2012 by

FRIDAY, May 4 – A study of seniors with non-small cell lung cancer found that older patients are less likely to receive treatment than younger patients, regardless of their overall health and prognosis. Non-small cell lung cancer is the most common type of lung cancer. For this study, U.S. researchers looked at data from more than 20,000 lung cancer patients aged 65 and older in the VA Central Cancer Registry between 2003 and 2008 and found that, for all stages of lung cancer, younger, sicker patients were more likely to receive treatment than otherwise healthy older patients. That may not be best for patients, the researchers said. Previous research has shown that older lung cancer patients who are otherwise healthy can benefit from treatment, while those with other illnesses are more vulnerable to the toxicity of cancer treatments. "It's clear that, as human beings and physicians, we ... Read more

Related support groups: Non-Small Cell Lung Cancer

Avastin No Benefit to Older Lung Cancer Patients: Study

Posted 17 Apr 2012 by

TUESDAY, April 17 – Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report. An earlier trial had found that Avastin (bevacizumab) did improve survival, but not in patients aged 65 and older. Even so, the researchers noted, most patients diagnosed with non-small cell lung cancer are 65 and older and Medicare still covers the cost of the drug. "A drug that we were just ecstatic about in 2006, we have to be more circumspect about," said lead researcher Dr. Deborah Schrag, an oncologist at Dana Farber, in Boston. Avastin should be used judiciously, she added, noting that "older patients should discuss it with their doctors, but we cannot say it provides a survival advantage based on these data." However, Schrag does not think Medicare ... Read more

Related support groups: Avastin, Non-Small Cell Lung Cancer, Bevacizumab

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Xeloda, Taxotere, Taxol, Xalkori, cisplatin, Gemzar, view more... cyclophosphamide, gemcitabine, paclitaxel, capecitabine, Iressa, Alimta, docetaxel, cetuximab, erlotinib, gefitinib, Gilotrif, bevacizumab, Abraxane, Platinol, vinorelbine, Navelbine, crizotinib, Trexall, amifostine, afatinib, Methotrexate LPF Sodium, Docefrez, Zykadia, paclitaxel protein-bound, Photofrin, Onxol, ceritinib, porfimer, pemetrexed, Folex PFS, Ethyol, Platinol-AQ